Pharmasset, Inc. Announces Proposed Public Offering of Common Stock

PRINCETON, N.J., Jan. 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. announced today that it has commenced an underwritten public offering, subject to market and other conditions, of $30,000,000 of its common stock pursuant to effective shelf registration statements. Pharmasset intends to grant to the underwriters a 30-day option to purchase up to an additional $4,000,000 of common stock. Leerink Swann LLC is acting as sole book-running manager for the offering.

The shares described above are being offered by Pharmasset pursuant to registration statements previously filed with and subsequently declared effective by the Securities and Exchange Commission. The transaction is subject to customary closing conditions.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on human immunodeficiency virus (HIV).

Pharmasset, Inc.


MORE ON THIS TOPIC